ReviewInternational journal of nanomedicine2026
Recent Progress in Selenium Nanomedicines for Ocular Diseases.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vision impairment represents a significant and growing global socioeconomic burden. In the elderly population, cataracts, age-related macular degeneration (AMD), glaucoma, and diabetic retinopathy (DR) are the predominant causes of visual loss. Conventional ophthalmic drug therapies are limited by low bioavailability and dose-related toxicity, highlighting the urgent need for safer and more effective treatments. Selenium (Se), an essential trace element, is critical for antioxidant defense, redox homeostasis, and immune regulation. Although the roles of elemental Se in ocular physiology and diseases are well-documented, its clinical application is constrained by its narrow therapeutic window and poor bioavailability. To overcome these limitations, Se nanoparticles (SeNPs) have emerged as a superior alternative, offering enhanced bioavailability, reduced toxicity, and the capability for targeted drug delivery. Strong preclinical evidence supports the therapeutic potential of Se nanomedicines in models of DR, retinal neovascularization, infectious keratitis, and cataracts. Significantly, the initial stages of clinical translation are in progress, as demonstrated by a pioneering Phase I trial involving CdSe/ZnS quantum dots (QDs) in patients with retinitis pigmentosa (RP), which has shown both tolerability and improvements in visual function. This review provides a comprehensive and up-to-date analysis of Se-based nanomedicines for ocular diseases, based on a literature search of PubMed, Scopus, Web of Science, and Google Scholar. It elucidates how SeNPs uniquely synergize intrinsic multi-mechanistic bioactivities (e.g., antioxidant, anti-angiogenic) with targeted and stimuli-responsive drug delivery, establishing them as versatile nanoplatforms with significant clinical translation potential for complex ocular pathologies. Therefore, further research is essential to optimize their design, elucidate their mechanisms of action, and ultimately facilitate their safe and effective clinical translation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.